We further developed cell models expressing differential CLDN9 expression levels and different hormonal receptor status, to confirm that in Her-2-positive breast cancer cells (SKBR3), knockdown of CLDN9 rendered the cells more sensitive to chemodrugs when Her-2 inhibitor is present. The gene discussed is ERBB2; the disease is breast carcinoma.